Revenue Growth Across Company
Q1 sales of $2.7 billion, up 6% year-over-year; guidance for constant currency sales growth of 5%–7% for 2026.
May 5th, 2026
Summary
- Earnings Call Date:
- 2026-05-05
- Change Since:
- -8.31%
- Next Earnings Date:
- 2026-08-10
Earnings Call Sentiment
PositiveThe call presented a largely constructive picture: solid top-line growth across surgical, vision care and ocular health, strong early adoption and share gains from new product launches (Unity, PanOptix Pro, Tryptyr, Total30), a meaningful equipment acceleration and a shareholder-friendly $1.5B repurchase plan. Offsetting this optimism were market headwinds (soft cataract volumes, China weakness), tariff-driven margin pressure, modest operational disruptions (Hydrus supply, Middle East shipping) and near-term margin timing (Q2 SG&A peak). Management maintained full-year guidance (5%–7% sales growth; 70–170 bps core operating margin expansion) and positioned the back half of 2026 for stronger contribution from new products, implying overall confidence in durable growth despite short-term noise.
Company Guidance
Alcon guided full‑year assumptions that aggregate eye‑care markets will grow 3–4% (at FX rates as of April‑end), and expects constant‑currency sales growth of 5–7%, core operating margin expansion of 70–170 basis points (with the majority of the improvement occurring in H2 and Q2 margin expected to be below last year due to seasonal SG&A), and core diluted EPS growth of 10–13%; the company now assumes an average U.S. import tariff rate of ~10% (vs. prior 15%), yielding an estimated $25 million reduction in tariff expense versus February guidance, with retaliatory tariffs unchanged and FX assumed to hold through year‑end; the Board approved a $1.5 billion share‑repurchase program over three years and shareholders approved a $0.28 per‑share dividend to be paid around May 7.
Surgical Franchise and Equipment Momentum
Surgical revenue $1.5 billion, up 6% YoY; equipment sales $253 million, up 23% driven by Unity platform adoption and early strong order pipeline.
Contact Lens and Vision Care Strength
Vision Care sales $1.2 billion, up 6% YoY; contact lens sales $738 million, up 4% driven by product innovation (Total30, Precision7) and reusable lens adoption (more than half of new wearers started reusables).
Ocular Health Momentum
Ocular health sales $487 million, up 10% YoY; sustained family of artificial tears grew high single-digits and multi-dose preservative-free formulations grew >20% YoY.
Pharmaceutical Launch Traction — Tryptyr
Tryptyr gained ~4 share points within ~8 months of launch, refill rates >70%, commercial coverage expanded to ~55% of commercial lives with Medicare Part D coverage targeted to expand access further.
IOL Innovation and Share Gains
PanOptix Pro drove share gains (nearly 2 share points in the U.S. PC-IOL category); global AT-IOL penetration up ~130 basis points to ~17% (excluding China up ~220 bps); TruPlus launched with toric option day 1; Vivity upgrade on track for early 2027.
Unity Recognition and Product Extensions
Unity VCS named an Edison Award winner; Unity CS (stand-alone cataract system) well received; Unity platform contributing to expanding installed base and equipment growth.
Capital Allocation and Shareholder Returns
Board approved $1.5 billion share repurchase program over 3 years and shareholders approved a $0.28 per share dividend, supporting return of capital while preserving investment capacity.
Operational Improvements and AI Adoption
Deployment of AI across R&D, operations and commercial functions to increase speed to approval, improve yield/quality and enable deeper customer insights; expected to fortify margin and productivity over time.
Operator
Greetings. Welcome to Alcon's First Quarter 2026 earnings call. [Operator Instructions] Please note that this conference is being recorded. At this time, I'll turn the conference over to Dan Cravens. Vice President and Global Head of Investor Relations. Thank you. You may now begin.
Daniel Cravens
Welcome to Alcon's First Quarter 2026 Earnings Conference Call. Yesterday, we issued our press release, Interim financial report and earnings presentation. All of these documents are available on our website at investor.alcon.com. Joining me on today's call are David Endicott, our Chief Executive Officer; and Tim Stonesifer, our Chief Financial Officer. Before we begin, please note that our press release, presentation and remarks today will include forward-looking statements, including statements regarding our future outlook. We undertake no obligation to update these statements as a result of new information or future events, except as required by law. Actual results may differ materially from those expressed or implied in these forward-looking statements. Please do not place undue reliance on them.
Important factors that could cause actual results to differ are included in our Form 20-F, earnings press release and inter financial report each of which is on file with the Securities and Exchange Commission and available on their website at sec.gov. We will discuss certain non-IFRS financial measures. These measures may be calculated differently from and may not be comparable to similar measures used by other companies. They should be considered in addition to and not as a substitute for IFRS pre...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free